|
|
| | Azumolene Basic information |
| Product Name: | Azumolene | | Synonyms: | Azumolene;1-[[[5-(4-Bromophenyl)-2-oxazolyl]methylene]amino]hydantoin;2,4-Imidazolidinedione, 1-[[[5-(4-bromophenyl)-2-oxazolyl]methylene]amino]-;EU4093 free base;SOCE,inhibit,Azumolene,EU-4093,ryanodine,Inhibitor,Ca channels,EU 4093,Calcium Channel,relaxant,Ca2+ channels,muscle,EU4093,receptor,calcium | | CAS: | 64748-79-4 | | MF: | C13H9BrN4O3 | | MW: | 349.14 | | EINECS: | | | Product Categories: | | | Mol File: | 64748-79-4.mol |  |
| | Azumolene Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 13.89 mg/mL (39.78 mM) |
| | Azumolene Usage And Synthesis |
| Originator | Azumolene sodium,ZYF Pharm Chemical | | Uses | Relaxant (skeletal muscle). | | Definition | ChEBI: Azumolene is a 1,3-oxazole which is substituted by a [(2,4-dioxoimidazolidin-1-yl)imino]methyl group at position 2 and a 4-bromophenyl group at position 5. It is a muscle relaxant used for the treatment/prevention of malignant hyperthermia. It has a role as a ryanodine receptor modulator and a muscle relaxant. It is a member of 1,3-oxazoles, a member of bromobenzenes and an imidazolidine-2,4-dione. It is a conjugate acid of an azumolene(1-). | | Manufacturing Process | To a stirred solution of 2-bromo-4'-bromoacetophenone (100.0 g, 0.36 mole)
in chloroform (500 ml) was added hexamethylenetetramine (50.0 g, 0.36
mole). The mixture was stirred for 2.5 h and 143.0 g of the product was
collected by filtration (100%).
The product above was combined with a solution of methanol (300 ml) and
conc. HCl (410 ml), and the mixture was stirred for 52 h. The solid was
collected by filtration and was washed with isopropanol. The product was
recrystallized from methanol (Darco) to give 55.0 g (61%, in three crops),
melting point 284°-287°C.
To a stirred mixture of the above amine hydrochloride (55.0 g, 0.22 mole) and
[[(2,4-dioxo-1-imidazolidinyl)imino]methyl]formyl chloride (42.0 g, 0.22 mole)
was added a solution of 440 ml of dimethylformamide and 44 ml of pyridine.
The mixture was stirred for 20 h and poured into 2 L of water. The solid was
collected by filtration and washed with ethanol and ether to give 36.0 g (28%)
of N-[2-(4-bromophenyl)-2-oxoethyl]-[[(2,4-dioxo-1-imidazolidinyl)-
imino]methyl]formamide, melting point 267°-269°C (recrystallization from
2200 ml acetic acid).
The of N-[2-(4-bromophenyl)-2-oxoethyl]-[[(2,4-dioxo-1-imidazolidinyl)
imino]methyl]formamide (22.0 g, 0.061 mole) was combined with phosphorus
oxychloride (310 ml) and the mixture was stirred and refluxed for 7 h. The
solid was filtered off and stirred into an ice and water mixture (1 L). The 15.0
g (70%) of 1-[[[5-(4-bromophenyl)-2-oxazolyl]methylene]amino]-2,4-
imidazolidinedione was collected by filtration, melting point 290°-292°C
(recrystallization from 700 ml acetic acid). | | Therapeutic Function | Muscle relaxant | | Biochem/physiol Actions | Azumolene, a more water-soluble analog of dantrolene, is a potent inhibitor of sarcoplasmic reticulum (SR) ryanodine receptor (RyR) that inhibits skeletal muscle SR Ca2+ release. Azumolene is a direct acting skeletal muscle relaxant that induces effective blockade of skeletal muscle RyR1. |
| | Azumolene Preparation Products And Raw materials |
|